Allogeneic hematopoietic SCT (HSCT) is the only curative therapy for several nonmalignant disorders in children and young adults. Limitations of HSCT in nonmalignant disorders include increased rates of graft failure (GF), infections, GVHD and early/late irreversible complications of conditioning regimens.
1,2 Recent studies using non-myeloablative or reduced-intensity conditioning (RIC) seek to limit side effects by using less intense, better tolerated regimens. There are emerging data on the use of TLI as part of the conditioning regimen in adults with malignant disease and its potential protective role against the development of posttransplant GVHD. 3 There are very limited data on the use of TLI in children with nonmalignant diseases. 4, 5 In an effort to achieve successful, stable donor engraftment and minimize early and late toxicities in high-risk patients with nonmalignant hematological disorders, we adopted a TLI-based RIC regimen before HLA-matched related HSCT.
We report on all children and adolescents with nonmalignant hematological diseases who received RIC allogeneic HSCT from matched family donors from October 2004 until September 2013. The study was reviewed and approved by the local institutional review board. All donors were HLA-A, B and DR Ag and allele matched. Mobilized PBSCs were used in all donors. Conditioning regimen consisted of a combination of oral BU 2 mg/kg given every 12 h for 2 days (days − 8 to − 7), fludarabine 35 mg/m 2 for 5 days from (days − 6 to − 2), horse antithymocyte globulin (ATG) 30 mg/kg daily for 5 days from (days − 6 to − 2) was used in the first 10 patients, whereas rabbit ATG at 2.5 mg/kg once daily for 3 consecutive days was used in the rest. TLI was administered as a single fraction of 500 cGy on day 0 before PBSC infusion for all patients. GVHD prophylaxis was with CsA and mycophenolate mofetil (MMF).
Thirty-seven patients received matched related allogeneic HSCT, 29 patients had thalassemia major, 3 pure red cell aplasia, 3 sickle cell disease, 1 infantile osteopetrosis and 1 autoimmune lymphoproliferative syndrome. Patient characteristics are summarized in Table 1 . The median age of the patients was 13 years (range, 0.3-25), and 16 (43%) were males. The median ferritin level was 1900 ng/dL (200-11 000). Twenty-six (70%) patients had liver biopsy that showed evidence of liver fibrosis, all of them had thalassemia major. Using the Pesaro risk classification all patients with thalassemia major were classified as class 3 at the time of transplant. 6 All donors were fully HLA matched, 33 (89%) were siblings and 4 (11%) were other family members (3 parents and 1 cousin). The median age of the donors was 13 years (range, 4-42). Donors were ABO incompatible in 9 cases (24%) and 25 (68%) were sex mismatched. All patients received PBSC, with median CD34+ cell count of 4.9 × 10 6 /kg recipient weight (range, 3.5-8.2). No donor needed central line insertion or experienced major side effects secondary to PBSC mobilization and collection. All patients achieved primary neutrophil engraftment at a median time of 15 days (range, 11-24). The median time for plt engraftment was 18 days (range, 15-74). Six patients (16.2%) with thalassemia major had secondary GF at 9, 10, 11, 15, 16 and 72 months following HSCT. Four of them are doing well now and are transfusion independent following second HSCT with the same preparative regimen except for elimination of TLI, and the other two are scheduled for a second transplant in the near future.
No patient required intensive care unit admission in the first 100 days following transplantation. Mild sinusoidal obstruction syndrome (SOS) developed in two patients (5%), both with thalassemia major and hepatitis C infection. Both were mild and treated with conservative and supportive measures. The median hospitalization period was 35 days (23-81). Twenty-six (70%) developed CMV reactivation but none of the patients developed CMV disease. A total of four patients (11%) developed grade II acute skin GVHD, all responded to first-line therapy. Chronic GVHD developed in three patients (8%), all were limited and resolved with first-line treatment. Seven patients remain on immune suppression at the last follow-up. Twenty-one patients (57%) had 490% donor chimerism within the first 100 days post transplantation. At the last follow-up, 26 patients (70%) had 490% donor chimerism, 6 (16%) had 475% and 5 (14%) o 75% donor chimerism. At a median follow-up of 31 months (range, 10-117), all patients are alive with no TRM. The 3-year probability of OS and EFS is 100% and 85%, respectively (Figure 1) .
Several groups have reported on the use of non-myeloablative conditioning or RIC in small numbers of children and young adults with nonmalignant diseases with variable degrees of success. 4, [7] [8] [9] [10] The use of non-myeloablative regimens was associated with GF in all patients. 7 Shenoy et al. reported on 10 patients with nonmalignant diseases who received related donor transplants using a novel RIC regimen with distal Campath-1 H (3 weeks pretransplant) in combination with fludarabine and melphalan. Although this regimen resulted in prompt engraftment in most patients, it was associated with significant viral activation and two (20%) patients died of transplant-related complications. 10 We describe the largest experience with using a TLI-based regimen in children and adolescents with nonmalignant diseases. We have used PBSC as the hematopoietic stem cell source in all patients to enhance the probability of engraftment. This regimen was very well tolerated with no patients experiencing TRM in this high-risk group of patients. None of the 10 patients with hepatitis C infection in our cohort had severe SOS post HSCT. We also observed very low rates of acute and chronic GVHD, which might be related to the use of TLI.
In conclusion, this RIC approach using TLI in children and adolescents with high-risk nonmalignant diseases resulted in excellent OS and EFS with no TRM and acceptable rates of acute and chronic GVHD. A prospective trial is planned using more intensive myelosuppression in combination with TLI and more prolonged post-transplant immune suppression, especially in patients with thalassemia major, to avoid secondary GF. Letter to the Editor
